This article first appeared on GuruFocus .
-
Revenue:Consolidated sales revenue was JPY578.2 billion, up JPY52.1 billion year on year.
-
Core Operating Income:Increased significantly to JPY62.3 billion, up JPY34.7 billion year on year.
-
Operating Income:JPY61 billion, up JPY35.6 billion year on year.
-
Net Income:Net income attributable to owners of the parent was JPY40.8 billion, up JPY45.3 billion from the prior year.
-
Segment - Agro and Life Solutions:Core operating income was JPY9.6 billion, an increase of JPY7.4 billion year on year.
-
Segment - ICT and Mobility Solutions:Core operating income was JPY13 billion, down JPY5.3 billion year on year.
-
Segment - Advanced Medical Solutions:Core operating loss was JPY1.9 billion, down JPY900 million year on year.
-
Segment - Essential and Green Materials:Core operating income was JPY27.2 billion, up JPY32.7 billion year on year.
-
Segment - Sumitomo Pharma:Core operating income was JPY18.8 billion, down JPY2.2 billion year on year.
-
Cash Flow from Operations:Positive at JPY5 billion, a decrease of JPY19 billion in cash inflows year on year.
-
Free Cash Flow:Negative JPY44.3 billion, a deterioration of JPY22.3 billion compared to the negative JPY21.9 billion in the prior year quarter.
-
DE Ratio:Improved significantly to 0.80 times from 0.93 times at the end of FY25.
Release Date: August 04, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Core operating income surged to JPY62.3 billion in Q1 FY2026, a significant increase from JPY27.7 billion in the prior year, marking the second-best Q1 on record.
-
Net income attributable to owners of the parent reached JPY40.8 billion, up JPY45.3 billion year-on-year, driven by strong core operating income growth.
-
The DE ratio improved significantly to 0.80 times from 0.93 times at the end of FY2025, supported by strong business performance and Sumitomo Pharma's capital increase.
-
Essential and green materials segment saw a substantial profit increase, with core operating income up JPY32.7 billion year-on-year, driven by improved margins at Petro Rabigh and inventory valuation gains.
-
Agro and life solutions segment reported a strong profit increase, with core operating income up JPY7.4 billion year-on-year, due to steady crop protection shipments and improved feed additive margins.
-
Semiconductor-related products in ICT and mobility solutions saw increased profits, driven by higher shipments due to growing demand for semiconductors.
-
The company provided a first-half FY2026 forecast with core operating income expected to double year-on-year, excluding gains on business sales, and net income expected to reach JPY70 billion.
-
Sumitomo Pharma's capital increase of JPY97.8 billion strengthened the balance sheet, contributing to the improved DE ratio.
-
The company maintained its annual dividend forecast of JPY16 per share, providing stability to shareholders.
-
Feed additive profits improved significantly due to rising market prices, with expectations of further price increases in Q2.
Negative Points
-
ICT and mobility solutions core operating income declined by JPY5.3 billion year-on-year, due to lower selling prices for polarizing films and the absence of a prior-year gain from the sale of the large LCD polarizing film business.
-
Display-related products faced challenges, including declining shipments due to a shortage of semiconductors and a sluggish mobile market.
-
Advanced medical solutions segment reported a core operating loss of JPY1.9 billion, down JPY900 million year-on-year, due to declined profit margins at affiliated companies and shipment timing differences.
-
Free cash flow deteriorated to a negative JPY44.3 billion, a JPY22.3 billion decline year-on-year, due to increased working capital and investment outflows.
-
The company refrained from revising its full-year forecast due to ongoing turmoil in the Middle East, citing difficulty in predicting future conditions.
-
Raw material prices, particularly NAFTA, continued to soar, with the company expecting the impact to persist, creating uncertainty for future margins.
-
Inventory levels in the distribution channel for crop protection products remain high in Central and Latin America, particularly in Brazil, posing a risk to future shipments.
-
The company expects a significant decrease in profit for Sumitomo Pharma in the first half due to the absence of gains from the sale of the Asian business and increased SG&A and R&D expenses in North America.
-
Cash flows from operating activities decreased by JPY19 billion year-on-year, primarily due to a temporary increase in working capital from the restart of the Chiba plant.
-
The company faces uncertainty in the feed additives market, as raw material prices continue to soar, making the outlook for the second half unclear.
Q & A Highlights
Q: What drove the significant improvement in core operating income in Q1 FY2026, and what are the key assumptions behind the newly issued first-half forecast? A: Toshihiro Yamauchi, Executive Officer and Director of Accounting, stated that core operating income increased significantly from JPY27.7 billion in Q1 FY2025 to JPY62.3 billion in Q1 FY2026, marking the second-best Q1 on record. The improvement was driven by better profit margins at Petro Rabigh and temporary inventory valuation gains in Essential and Green Materials, strong shipments of crop protection products and better margins for feed additives in Agro & Life Solutions, and increased shipments of semiconductor processing materials in ICT & Mobility Solutions. For the first half of FY2026, the company forecasts core operating income of JPY125 billion and net income of JPY70 billion, assuming an exchange rate of JPY157 to the dollar and a Naphtha price of JPY104,000 per kiloliter. The full-year forecast remains unchanged due to ongoing Middle East turmoil.
Q: Can you provide a breakdown of the Agro & Life Solutions Q1 performance and the outlook for Q2, particularly regarding methionine and crop protection? A: The company representative explained that the Q1 profit of JPY9.6 billion (up from JPY2.2 billion last year) was mainly driven by methionine feed additives, where prices rose due to tightening supply-demand from the Middle East situation. Crop protection was not a major factor in Q1 as it is not the busy season. For Q2, the company expects a significant profit increase of JPY35 billion year-on-year, with more than half coming from crop protection and over JPY10 billion from feed additives. The Q2 improvement is based on Brazil and Latin America entering their high-demand season, India recovering from monsoon delays, and further price increases for feed additives.
Q: How will the El Nino impact affect crop protection demand across different regions? A: The company representative noted that El Nino primarily impacts the southern hemisphere, causing reduced precipitation and higher temperatures. In Brazil, the northern part may see negative impacts on planting but increased pest pressure (a positive for pesticide demand), while the southern part faces flood risks. India is already seeing delayed monsoons, pushing planting later, though recovery is starting in July. Southeast Asia and Australia may see similar patterns of reduced rain and higher temperatures, which could increase pest populations and potentially benefit crop protection demand.
Q: Why is the ICT & Mobility Solutions segment expected to remain relatively flat from Q1 to Q2 despite growth in semiconductor-related products? A: The company representative explained that while semiconductor-related products are expected to grow steadily, the segment will face increased fixed costs from Q2 onwards due to ongoing investments in semiconductor-related areas. Display-related products are expected to improve slightly from Q1 to Q2, but the large-size display business is being wound down, and the memory chip shortage is impacting mid-to-low-end touch screen panels. The mobility segment is expected to see a slight decline due to no major positive factors.
Q: What is the outlook for the Essential and Green Materials segment from Q1 to Q2, and what is the current utilization situation in Japan and Singapore? A: The company representative stated that the Q1 to Q2 change is primarily driven by Petro Rabigh's equity method income (JPY9 billion in Q1, JPY17 billion expected in Q2) and inventory valuation effects. The Q1 inventory valuation gain of JPY15 billion is expected to turn negative in Q2 as Naphtha prices are assumed to decline. Utilization rates in Japan and Singapore remain unchanged from Q1, with no plans to increase utilization in the near term. The company is operating in line with customer demand and has secured necessary raw materials.
Q: Regarding methionine, will the market price continue to rise from Q1 to Q2, and what is the capacity utilization outlook? A: The company representative confirmed that while spot prices may have peaked, the company's contract-based sales create a time lag, so Q2 prices will reflect the earlier spot price increases. The company is maintaining full capacity operation of 180,000 tons per year. For the second half, forecasting remains difficult, which is why the full-year forecast has not been revised. The company will reassess when announcing first-half results.
Q: Can you break down the volume and price factors for the ICT & Mobility Solutions segment, particularly regarding the positive and negative contributions? A: The company representative explained that positive factors include semiconductor materials (contributing several tens of billions of yen, including a JPY15 billion positive impact from yen depreciation) and mobility products benefiting from China's consumer electronics replacement policy. Negative factors include display-related products, the absence of last year's gain from the sale of the large-size LCD business, and the impact of memory chip shortages on touch screen panels. The price optimization in mobility reflects passing on increased raw material costs, though the impact on core operating income is minimal.
Q: What is the regional breakdown for crop protection sales in Q1, and how does the inventory situation vary across distribution channels? A: The company representative stated that North America was flat to slightly down on a dollar-denominated basis due to shipment timing, while Central and Latin America saw significant increases with some front-loading from Q2. India saw a slight decline due to monsoon delays shifting shipments to Q2. Inventory levels in North America, India, and Europe have reached optimal levels, but Brazil still has rather high inventory in the distribution channel. For Q2, all regions are expected to grow year-on-year, with Latin America contributing the largest profit increase as it recovers from previous sluggishness.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
